Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:PHARNYSE:PRD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumePHARPharming Group$11.97+3.9%$9.49$6.65▼$12.61$813.99M0.026,228 shs796 shsPRD(PRD)$0.13$18.96▼$23.10N/AN/A10,130 shs5,010 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformancePHARPharming Group-1.99%-4.89%+17.95%+32.32%+32.93%PRD(PRD)0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationPHARPharming Group2.2226 of 5 stars3.53.00.00.02.60.00.6PRD(PRD)N/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PricePHARPharming Group 3.00Buy$30.00150.73% UpsidePRD(PRD) 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest PRD, PHAR, FOG, and ZPHR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/20/2025PHARPharming GroupHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$37.00 ➝ $37.003/14/2025PHARPharming GroupOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$30.00 ➝ $39.003/14/2025PHARPharming GroupHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$37.00 ➝ $37.00(Data available from 6/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookPHARPharming Group$320.71M2.54$0.13 per share91.82$3.26 per share3.67PRD(PRD)N/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DatePHARPharming Group-$10.55M-$0.20N/A398.83N/A-6.09%-7.65%-3.82%7/30/2025 (Estimated)PRD(PRD)N/AN/A0.00N/AN/AN/AN/AN/AN/ALatest PRD, PHAR, FOG, and ZPHR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025PHARPharming Group-$0.25-$0.22+$0.03-$0.22$67.74 million$79.09 million3/13/2025Q4 2024PHARPharming Group$0.07$0.05-$0.02$0.05$76.67 million$92.70 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthPHARPharming GroupN/AN/AN/AN/AN/APRD(PRD)N/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioPHARPharming Group0.413.532.76PRD(PRD)N/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipPHARPharming Group0.03%PRD(PRD)N/AInsider OwnershipCompanyInsider OwnershipPHARPharming Group2.07%PRD(PRD)N/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionablePHARPharming Group28068.03 million66.62 millionNot OptionablePRD(PRD)N/AN/AN/ANot OptionablePRD, PHAR, FOG, and ZPHR HeadlinesRecent News About These CompaniesRedburn Atlantic Upgrades Charles Schwab Corporation - Preferred Stock (SCHW.PRD)June 12 at 4:23 AM | msn.comThe Indonesian People’s Movement Need to Build a Political PartyJune 11 at 3:58 PM | socialistproject.caKerala +1 Results 2025 Date, Time: Plus One results likely to be announced on June 3June 2, 2025 | indianexpress.comPrinceton Research Day 2025: A pipeline of talent and commitmentMay 31, 2025 | princeton.eduKerala rains: Malankara dam shutters opened without warning; water level rises in Thodupuzha, Muvattupuzha riversMay 26, 2025 | english.mathrubhumi.comKerala DHSE Plus 2 Result 2025 Live: Kerala 12th HSE results out, direct linkMay 22, 2025 | msn.comKerala Board 12th Result 2025: KBPE Second Year Result with Saphalam, PRD LIVE, DigiLocker Mobile App and Download Marksheet OnlineMay 22, 2025 | jagranjosh.comDHSE Kerala Plus Two Result 2025: How to Check Kerala 12th Results Online, Via SMS, Digi Locker and Mobile App?May 21, 2025 | timesnownews.comPlus Two results on mobile apps tooMay 21, 2025 | thehindu.comFive held after Kanpur police bust extortion gang led by traffic SI, home guard, female PRD jawanMay 20, 2025 | thehindu.comUndercover Heist: The Faux STF Police ScandalMay 20, 2025 | devdiscourse.comMorgan Stanley Upgrades KKR & Co. Inc. - Preferred Stock (KKR.PRD)May 14, 2025 | msn.comSSLC Result Kerala 2025: Check KBPE 10th Result with Saphalam, PRD LIVE, DigiLocker Mobile AppMay 9, 2025 | timesnownews.comKerala Board 10th Result 2025: KBPE 10th Result with Saphalam, PRD LIVE, DigiLocker Mobile App and Download Marksheet OnlineMay 9, 2025 | jagranjosh.comKerala SSLC Result 2025 to Be Declared Today at 3 PM: Check Scores OnlineMay 9, 2025 | dailypioneer.comKerala SSLC 10th Result 2025, Keralaresults.nic.in LIVE: 99.5% pass, Thiruvananthapuram lowest percentageMay 9, 2025 | indianexpress.comPiper Sandler Upgrades Rithm Capital - Preferred Stock (RITM.PRD)April 29, 2025 | msn.comAUA 2025: Primary Resistance to Nivolumab plus Ipilimumab Therapy Affects Second-Line Treatment Outcomes in Patients with mRCCApril 27, 2025 | urotoday.comDeveloper wants to build homes at site of former Mineral Beach poolApril 24, 2025 | observer-reporter.comCitigroup Initiates Coverage of Ford Motor Company - Corporate Bond (F.PRD) with Neutral RecommendationApril 24, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeThese Are the Only 6 Stock Stocks in NVIDIA's 13F PortfolioBy Leo Miller | May 22, 2025View These Are the Only 6 Stock Stocks in NVIDIA's 13F PortfolioPharma Fire Sale: 3 Stocks the RSI Says You Shouldn’t IgnoreBy Sam Quirke | May 14, 2025View Pharma Fire Sale: 3 Stocks the RSI Says You Shouldn’t IgnoreEli Lilly : A Breakout Biotech Powerhouse With Room to RunBy Jeffrey Neal Johnson | May 29, 2025View Eli Lilly : A Breakout Biotech Powerhouse With Room to RunAnalysts Can't Get Enough of These Little-Known Biopharma StocksBy Nathan Reiff | June 12, 2025View Analysts Can't Get Enough of These Little-Known Biopharma StocksPRD, PHAR, FOG, and ZPHR Company DescriptionsPharming Group NASDAQ:PHAR$11.96 +0.45 (+3.86%) As of 09:30 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.(PRD) NYSE:PRDPRD Energy Inc. is a Canada-based development-stage company. The Company is seeking, planning or executing field operations on farm-in arrangements with certain oil and gas operators located in Germany, and certain exploration and production licenses in Germany. The Company owns two wholly owned German subsidiaries, PRD Energy GmbH and PRD GmbH. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Ignore the Noise—Samsara Stock Is Still a Strong Buy Oracle’s Cloud Boom Is Just Getting Started Netflix Sets New Highs—Price Targets Keep Climbing IonQ’s $1B Acquisition and Drug Discovery Leap With NVIDIA Alibaba’s Dip Is a Gift—Here’s the Price That Matters Betting on Disruption: Is Lemonade the Future of Insurance? Starbucks Stock: Culture Fix May Be Key to Long-Term Growth GameStop Turns a Profit, But Core Business Keeps Shrinking Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
